Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Zimran

Showing results (181-190 of 238) with videos related to

Pageof 24
Sort By:
Neurology. Genetics|April 29, 2016
Clinical course and prognosis in patients with Gaucher disease and parkinsonismGrisel Lopez, Jenny Kim, Edythe Wiggs, et al.
Blood Cells, Molecules & Diseases|December 7, 2007
Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic interventionPeter J Meikle, Philip D Whitfield, Tina Rozaklis, et al.
Journal of Clinical Medicine|September 9, 2022
Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, et al.
International Journal of Molecular Sciences|February 15, 2022
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?Tama Dinur, Peter Bauer, Christian Beetz, et al.
American Journal of Hematology|September 29, 2018
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trialElena Lukina, Nora Watman, Marta Dragosky, et al.
Journal of Inherited Metabolic Disease|August 2, 2018
Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfaAri Zimran, Tama Dinur, Shoshana Revel-Vilk, et al.
Journal of Clinical Medicine|June 28, 2023
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). <i>J. Clin. Med.</i> 2022, <i>11</i>, 5158"Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, et al.
Blood Cells, Molecules & Diseases|November 12, 2010
The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher RegistryBarry Rosenbloom, Manisha Balwani, Jeff M Bronstein, et al.
Blood Cells, Molecules & Diseases|May 21, 2013
Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort studyDavid J Kuter, Atul Mehta, Carla E M Hollak, et al.
Blood Cells, Molecules & Diseases|May 20, 2014
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatmentElena Lukina, Nora Watman, Marta Dragosky, et al.
Pageof 24

Showing results (181-190 of 238) with videos related to

Sort By:
Pageof 24
Neurology. Genetics|April 29, 2016
Clinical course and prognosis in patients with Gaucher disease and parkinsonismGrisel Lopez, Jenny Kim, Edythe Wiggs, et al.
Blood Cells, Molecules & Diseases|December 7, 2007
Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic interventionPeter J Meikle, Philip D Whitfield, Tina Rozaklis, et al.
Journal of Clinical Medicine|September 9, 2022
Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, et al.
International Journal of Molecular Sciences|February 15, 2022
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?Tama Dinur, Peter Bauer, Christian Beetz, et al.
American Journal of Hematology|September 29, 2018
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trialElena Lukina, Nora Watman, Marta Dragosky, et al.
Journal of Inherited Metabolic Disease|August 2, 2018
Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfaAri Zimran, Tama Dinur, Shoshana Revel-Vilk, et al.
Journal of Clinical Medicine|June 28, 2023
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). <i>J. Clin. Med.</i> 2022, <i>11</i>, 5158"Derralynn A Hughes, Patrick Deegan, Pilar Giraldo, et al.
Blood Cells, Molecules & Diseases|November 12, 2010
The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher RegistryBarry Rosenbloom, Manisha Balwani, Jeff M Bronstein, et al.
Blood Cells, Molecules & Diseases|May 21, 2013
Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort studyDavid J Kuter, Atul Mehta, Carla E M Hollak, et al.
Blood Cells, Molecules & Diseases|May 20, 2014
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatmentElena Lukina, Nora Watman, Marta Dragosky, et al.
Pageof 24